State-owned Aerospace Industrial Development Corp (AIDC, 漢翔航空) is facing promising prospects for the coming years, with an advanced trainer program in the works and the likelihood of a major role in a possible F-16A/B upgrade project.
One of the main projects AIDC is working on is a new advanced and completely indigenous trainer, Mike Lee (李適彰), secretary-general of the National Defense Industrial Association of Sino (中華國防工業發展協會), told the Taipei Times on the sidelines of the Taipei Aerospace and Defense Technology Exhibition yesterday.
The firm has been working on a XAT-5 prototype, a twin-engine trainer that, according to some industry analysts, could be based on the Indigenous Defense Fighter’s (IDF) airframe.
Photo: J. Michael Cole, Taipei Times
Although he would not provide a time frame and said the air force had yet to green-light a specific model, Lee, who also serves as a special assistant to AIDC chairman Jason Liu (劉介岑), said the next few years would be the perfect time to introduce a new trainer to replace the twin-engine AT-3 — also manufactured by AIDC — that entered service in 1984.
Turning to the mid-life upgrade of Taiwan’s 130 F-CK-1A/B “Ching Kuo” IDFs, Lee said work on the first 71 aircraft was continuing and provided the air force had the budget, a second-phase upgrade, which would complete the remainder of the fleet, could be launched at some point. The first phase of the program has delivered six upgraded aircraft so far.
The configurations involved in the second-phase upgrades are still under discussion between AIDC and the air force, Lee said.
AIDC is also likely to play a role on the Lockheed Martin F-16s.
Not only could the firm be assigned some subcontracting work on the 66 new F-16C/Ds Taiwan has been requesting from the US since 2007, but the previous day a senior official at Lockheed told the Taipei Times that most of the work on the US$4.5 billion program to upgrade Taiwan’s 144 F-16A/Bs would be carried out in Taiwan.
Given the great similarities between the IDF and the F-16, and AIDC’s experience handling both, it is very likely that AIDC would get the contract for the F-16A/B upgrade, though ultimately the decision lies with the air force, Lee said.
The US is expected to announce its final decision on the F-16C/D sale and the F-16A/B upgrade package on Oct. 1.
It has been speculated that if Taiwan fails to obtain the F-16C/Ds, AIDC could proceed with the manufacture of the IDF-II “Goshawk” joint strike fighter, which comes with a larger payload and what is known as a conformal fuel tank that provides greater range.
A model Goshawk was displayed at the launch ceremony for the refurbished IDFs in Greater Taichung on June 30.
Depending on budgets and requirements set by the air force, Lee said AIDC could also embark on a fifth-generation fighter aircraft development program, but he did not elaborate nor did he tie a decision to any outcome on the F-16C/Ds.
Although it could have its hands full if all the programs were to occur simultaneously, Lee said AIDC currently had the manpower and technical base to accomplish all of the tasks.
BREAKING RECORDS: Kuo Hsing-chun’s snatch, clean and jerk, and combined lifts were all Olympic records, although well off her combined world record Taiwanese weightlifter Kuo Hsing-chun (郭婞淳) yesterday completed her elusive quest for Olympic gold, clinching Taiwan’s first win at the Tokyo Games as she set Olympic records in the women’s under-59kg weight class. Kuo, who has not lost a major competition in her weight class since the 2016 Olympics in Rio de Janeiro, where she was hampered by injury and finished third, finally chased down the gold medal that had long remained just out of her grasp. The 27-year-old finished with a combined lift of 236kg — 103kg in the snatch and 133kg in the clean and jerk — 21kg more
NEXT ROUND: About 1.44 million people who have registered online to receive the AstraZeneca vaccine are to get text messages today to book a vaccine appointment Strict border control measures, including a ban on foreign nationals entering or transiting through Taiwan, are to continue, the Central Epidemic Command Center (CECC) said yesterday, as it reported 10 locally transmitted COVID-19 infections and no deaths. Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the center, said five of the cases tested positive during isolation or upon ending it. The sources of infection of eight cases have been identified, one remains unclear and one is under investigation, he said, adding that 87.8 percent of the people infected with COVID-19 since May 11 have been released from isolation. Chen said an
STAY VIGILANT: Although a level 2 alert would raise the limit on indoor gatherings to 50, people should still wear masks and practice social distancing, the center said A nationwide COVID-19 alert is to be lowered from level 3 to 2 on Tuesday, but strict border controls would remain, the government said yesterday. The level 3 alert in place since May 19 is to end on Monday, with a level 2 alert in place from Tuesday until Aug. 9, the Executive Yuan said. Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the Central Epidemic Command Center (CECC), told a news conference in Taipei that over the next two weeks, people should still wear masks at all times outdoors, except while eating or drinking, and practice social distancing. The maximum
THE HOME TEAM: DPP Legislator Kao Chia-yu said she canceled her booking for an AstraZeneca shot as soon as she heard that the Medigen vaccine was an option President Tsai Ing-wen (蔡英文) yesterday said that she would get inoculated with the COVID-19 vaccine manufactured by Taiwan-based Medigen Vaccine Biologics Corp (高端疫苗). Tsai wrote on Facebook that she had registered for her first vaccine dose using the national online COVID-19 vaccination booking system, which allows people to indicate their preferred vaccine brand and to make an appointment when the shot becomes available. Tsai said that she opted for the Medigen vaccine — one of three now available on the system, along with the AstraZeneca and Moderna vaccines — even though Medigen has yet to deliver any doses or provide a